Showing results (321-330 of 344) with videos related to

Sort By:
Pageof 35
Haematologica|March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasoneCarmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Leukemia|June 18, 2025
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemiaFilippo Vit, Tamara Bittolo, Antonella Zucchetto, et al.
Blood|October 21, 2011
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotypeVera Grossmann, Enrico Tiacci, Antony B Holmes, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trialsMassimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
American Journal of Hematology|January 14, 2014
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patientsRobin Foà, Ilaria Del Giudice, Antonio Cuneo, et al.
Hemasphere|June 8, 2026
Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trialNawar Maher, Riccardo Moia, Mohammad Almasri, et al.
European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Pageof 35